Abstract
Background: Epidermal Growth Factor Receptor (EGFR) is overexpressed in a variety of cancers and is associated with poor prognosis, low survival rate, and resistance of cancer cells to treatment.
Objective: This review discusses the combined effect of EGFR inhibitor and radiation therapy in cancer treatment.
Method: The recent literature and patent applications were considered in which the role of EGFR in cancer and EGFR inhibitors, as well as the preclinical and clinical studies are related to synergistic effects of EGFR inhibitors and ionizing radiation in the treatment of various cancers.
Results: The specific inhibition has been introduced as targeted therapy for treatment of cancers. Two major pharmacological approaches for inhibition of EGFR are monoclonal antibodies and smallmolecule tyrosine kinase inhibitors. The use of these agents in combination with ionizing radiation results in increasing the cytotoxicity on tumors that are rich in expression of EGFR.
Conclusion: The combination of EGFR inhibitor and ionizing radiation has synergistic effect and resulted in improvement of radiotherapy in patients.
Keywords: Cancer, EGFR, monoclonal antibodies, radiation therapy, sensitizing, tyrosine kinase inhibitors.
Recent Patents on Anti-Cancer Drug Discovery
Title:Synergistic Effect of Epidermal Growth Factor Receptor Inhibitors and Ionization Radiation in Cancer Treatment
Volume: 12 Issue: 4
Author(s): Zahra Shaghaghi and Seyed Jalal Hosseinimehr*
Affiliation:
- Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari,Iran
Keywords: Cancer, EGFR, monoclonal antibodies, radiation therapy, sensitizing, tyrosine kinase inhibitors.
Abstract: Background: Epidermal Growth Factor Receptor (EGFR) is overexpressed in a variety of cancers and is associated with poor prognosis, low survival rate, and resistance of cancer cells to treatment.
Objective: This review discusses the combined effect of EGFR inhibitor and radiation therapy in cancer treatment.
Method: The recent literature and patent applications were considered in which the role of EGFR in cancer and EGFR inhibitors, as well as the preclinical and clinical studies are related to synergistic effects of EGFR inhibitors and ionizing radiation in the treatment of various cancers.
Results: The specific inhibition has been introduced as targeted therapy for treatment of cancers. Two major pharmacological approaches for inhibition of EGFR are monoclonal antibodies and smallmolecule tyrosine kinase inhibitors. The use of these agents in combination with ionizing radiation results in increasing the cytotoxicity on tumors that are rich in expression of EGFR.
Conclusion: The combination of EGFR inhibitor and ionizing radiation has synergistic effect and resulted in improvement of radiotherapy in patients.
Export Options
About this article
Cite this article as:
Shaghaghi Zahra and Hosseinimehr Jalal Seyed*, Synergistic Effect of Epidermal Growth Factor Receptor Inhibitors and Ionization Radiation in Cancer Treatment, Recent Patents on Anti-Cancer Drug Discovery 2017; 12 (4) . https://dx.doi.org/10.2174/1574892812666170829150057
DOI https://dx.doi.org/10.2174/1574892812666170829150057 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Thymoquinone Effects on Cell Viability, Apoptosis and VEGF-A Gene Expression Level in AGS(CRL-1739) Cell Line
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot Topic: Anti-Cancer Drugs (Executive Editor: Elke S. Bergmann-Leitner)]
Current Pharmaceutical Design B-Lymphocytes Govern the Pathogenesis of Sjogren's Syndrome
Current Pharmaceutical Biotechnology HER3 and its Ligand, Heregulin, as Targets for Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Cancer Epigenetics: Clinical Perspectives
Current Cancer Drug Targets Chalcones Derivatives Acting as Cell Cycle Blockers: Potential Anti Cancer Drugs?
Current Drug Targets Novel Drugs and the Response to Hypoxia: HIF Stabilizers and Prolyl Hydroxylase
Recent Patents on Cardiovascular Drug Discovery 3-Carboranyl Thymidine Analogues (3CTAs) and Other Boronated Nucleosides for Boron Neutron Capture Therapy
Anti-Cancer Agents in Medicinal Chemistry Genomic Sequencing of Key Genes in Mouse Pancreatic Cancer Cells
Current Molecular Medicine Immunotherapeutic Impact of Toll-like Receptor Agonists in Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Dendrimers in Therapy for Breast and Colorectal Cancer
Current Medicinal Chemistry Exploiting Cyclooxygenase-(in)Dependent Properties of COX-2 Inhibitors for Malignant Glioma Therapy
Anti-Cancer Agents in Medicinal Chemistry Multitargeted Molecular Docking Study of Natural-Derived Alkaloids on Breast Cancer Pathway Components
Current Computer-Aided Drug Design Eradicating the Roots: Advanced Therapeutic Approaches Targeting Breast Cancer Stem Cells
Current Pharmaceutical Design Women Tipping the Scale During Pregnancy: A Special Population for Obesity Interventions,Treatments and Clinical Trials
Current Pharmaceutical Design Adalimumab
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Exposure of B Cell Chronic Lymphocytic Leukemia (B-CLL) Cells to Nutlin-3 Induces a Characteristic Gene Expression Profile, which Correlates with Nutlin-3-Mediated Cytotoxicity (Supplementry Table)
Current Cancer Drug Targets Prognostic Value of CD34 Positive Cells in the Lumen of Tumor Vessels in Breast Cancer
Current Angiogenesis (Discontinued) Functional Evaluation of Imatinib mesylate in Hepatocellular Carcinoma Cells
Recent Patents on Biomarkers Telomere Shortening Is a Sole Mechanism of Aging in Mammals
Current Aging Science